Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Aduhelm
Aduhelm
Scandal aside, Biogen's Aduhelm sales set to reach $1B next year and $6B+ by 2025: analysts
Fierce Pharma
Tue, 07/20/21 - 12:37 pm
Biogen
Aduhelm
Alzheimer's disease
Biogen, ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
Fierce Pharma
Fri, 07/16/21 - 10:35 am
Biogen
Aduhelm
ICER
Major health centers, insurers push back against Aduhelm
BioPharma Dive
Thu, 07/15/21 - 11:16 pm
Biogen
Aduhelm
insurers
Alzheimer's disease
FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
Stat
Wed, 07/14/21 - 10:37 pm
Janet Woodcock
FDA
Biogen
Aduhelm
Alzheimer's disease
Private insurers decline to cover Biogen's new Alzheimer's drug in escalating standoff — report
Endpoints
Wed, 07/14/21 - 10:50 am
Biogen
Aduhelm
insurers
Alzheimer's disease
FDA staffers defend Aduhelm approval in JAMA editorial
Pharmaforum
Wed, 07/14/21 - 10:18 am
FDA
Biogen
Aduhelm
JAMA
drug approvals
Alzheimer's disease
So far, so not-so-good: Neurologists slow to warm up to Biogen’s Alzheimer drug Aduhelm, study finds
Fierce Pharma
Tue, 07/13/21 - 11:43 pm
Biogen
Aduhelm
neurologists
Alzheimer's disease
House committees kick off investigation into how Biogen's Aduhelm won approval
Endpoints
Tue, 07/13/21 - 10:48 am
US Congress
Biogen
Aduhelm
FDA
drug approvals
Alzheimer's disease
Medicare to weigh nationwide coverage rules for Biogen Alzheimer's drug
BioPharma Dive
Mon, 07/12/21 - 11:39 pm
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
FDA Head Calls for Inspector General Investigation of Aduhelm Approval
BioSpace
Sat, 07/10/21 - 12:01 am
FDA
Janet Woodcock
Biogen
Aduhelm
FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment
BioPharma Dive
Thu, 07/8/21 - 11:17 am
Biogen
Aduhelm
FDA
Alzheimer's disease
labeling
Aduhelm’s accelerated approval offers a promising roadmap for rare neurological diseases
Stat
Wed, 07/7/21 - 10:36 pm
FDA
Biogen
Aduhelm
accelerated approvals
neurodegenerative disease
Calls grow for an investigation into FDA approval of Biogen’s Alzheimer’s drug
Stat
Wed, 06/30/21 - 10:20 pm
FDA
Biogen
Aduhelm
drug approvals
ICER finds Biogen’s new exorbitantly priced Alzheimer’s drug doesn’t match even an optimistic view of potential clinical benefits
Endpoints
Wed, 06/30/21 - 11:04 am
Biogen
ICER
Aduhelm
Alzheimer's disease
drug pricing
FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report
Endpoints
Tue, 06/29/21 - 11:05 am
FDA
Biogen
Aduhelm
accelerated approvals
Alzheimer's disease
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
Stat
Mon, 06/28/21 - 10:44 am
Biogen
Aduhelm
FDA
Medicare
Alzheimer's disease
Biogen says it may adjust Aduhelm price if more patients take it than expected
Beckers Hospital Review
Fri, 06/25/21 - 11:00 am
Biogen
Aduhelm
drug pricing
Alzheimer's disease
Warren, Cassidy want hearing on new Alzheimer's drug coverage
The Hill
Thu, 06/24/21 - 11:07 am
Senate
Biogen
Aduhelm
Medicare
Alzheimer's disease
Bill Cassidy
Elizabeth Warren
FDA documents show how controversial Alzheimer's drug decision was reached
BioPharma Dive
Tue, 06/22/21 - 10:50 pm
Biogen
Aduhelm
FDA
Alzheimer's disease
Woodcock defends Biogen's new Alzheimer's drug, says it has more supportive data than many past accelerated approvals
Endpoints
Tue, 06/22/21 - 10:34 pm
FDA
Janet Woodcock
Biogen
Aduhelm
Alzheimer's disease
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
next ›
last »